Improving the efficacy of RAAS blockade in patients with chronic kidney disease

Nature Reviews Nephrology

Volumn 9, Issue 2, 2013, Pages 112-121

  Lambers Heerspink, Hiddo J ^a   De Borst, Martin H ^a   Bakker, Stephan J L ^a   Navis, Gerjan J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN I; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSIN[1-7]; BRAIN NATRIURETIC PEPTIDE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; POTASSIUM; REMIKIREN;

ACUTE KIDNEY FAILURE; ADVERSE OUTCOME; ALBUMINURIA; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DIURETIC THERAPY; DRUG EFFICACY; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; HORMONE RESPONSE; HUMAN; HYPERKALEMIA; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY INJURY; LIFESTYLE MODIFICATION; MACROALBUMINURIA; MEAN ARTERIAL PRESSURE; MICROALBUMINURIA; NONHUMAN; OPTIMAL DRUG DOSE; POTASSIUM BALANCE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN RESTRICTION; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR DISEASE; REVIEW; SALT INTAKE; SODIUM EXCRETION; SODIUM INTAKE; SODIUM RESTRICTION; SODIUM URINE LEVEL; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION;

GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES; HUMANS; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PEPTIDE FRAGMENTS; RENAL INSUFFICIENCY, CHRONIC; RENIN; RENIN-ANGIOTENSIN SYSTEM; SODIUM CHLORIDE, DIETARY;

EID: 84873162767     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2012.281     Document Type: Review

References (86)

1. American Diabetes Association. Standards of medical care in diabetes -2012. Diabetes Care 35 (Suppl. 1), S11-S63 (2012).
2. Kidney Disease Outcomes Quality Initiative. Clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am. J. Kidney Dis. 43 (Suppl. 1), S1-S290 (2004).
3. Burgess, E. et al. Supramaximal dose of candesartan in proteinuric renal disease. J. Am. Soc. Nephrol. 20, 893-900 (2009).
4. Weir, M. R. et al. Antihypertensive effects of double the maximum dose of valsartan in African-American patients with type 2 diabetes mellitus and albuminuria. J. Hypertens. 28, 186-193 (2010).
5. Heeg, J. E., de Jong, P. E., van der Hem, G. K. & de Zeuuw, D. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int. 36, 272-279 (1989).
6. Kunz, R., Friedrich, C., Wolbers, M. & Mann, J. F. Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann. Intern. Med. 148, 30-48 (2008).
7. Jennings, D. L., Kalus, J. S., Coleman, C. I., Manierski, C. & Yee, J. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: A meta-analysis. Diabet. Med. 24, 486-493 (2007).
8. MacKinnon, M. et al. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: A systematic review of the efficacy and safety data. Am. J. Kidney Dis. 48, 8-20 (2006).
9. Laverman, G. D., Navis, G., Henning, R. H., de Jong, P. E. & de Zeeuw, D. Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int. 62, 1020-1025 (2002).
10. Esnault, V. L., Ekhlas, A., Nguyen, J. M. & Moranne, O. Diuretic uptitration with half dose combined ACEI+ARB better decrease proteinuria than combined ACEI+ARB uptitration. Nephrol. Dial. Transplant. 25, 2218-2224 (2010).
11. Lambers-Heerspink, H. J., Perkovic V. & de Zeeuw, D. Renal and cardio-protective effects of direct renin inhibition: A systematic literature review. J. Hypertens. 27, 2321-2331 (2009).
12. van Paassen, P., de Zeeuw, D., Navis, G. & de Jong, P. E. Renal and systemic effects of continued treatment with renin inhibitor remikiren in hypertensive patients with normal and impaired renal function. Nephrol. Dial. Transplant. 15, 637-643 (2000).
13. Persson, F. et al. Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetes Care 32, 1873-1879 (2009).
14. Parving, H. H. et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N. Engl. J. Med. 358, 2433-2446 (2008).
15. Waanders, F. et al. Aldosterone, from (patho)physiology to treatment in cardiovascular and renal damage. Curr. Vasc. Pharmacol. 9, 594-605 (2011).
16. Blasi, E. R. et al. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int. 63, 1791-1800 (2003).
17. Nagase, M. et al. Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress. Hypertension 50, 877-883 (2007).
18. Kramer, A. B., van der Meulen, E. F., Hamming, I., van Goor, H. & Navis, G. Effect of combining ACE inhibition with aldosterone blockade on proteinuria and renal damage in experimental nephrosis. Kidney Int. 71, 417-424 (2007).
19. Rossing, K., Schjoedt, K. J., Smidt, U. M., Boomsma, F. & Parving, H. H. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: A randomized, double-masked, cross-over study. Diabetes Care 28, 2106-2112 (2005).
20. van den Meiracker, A. H. et al. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function. J. Hypertens. 24, 2285-2292 (2006).
21. Schjoedt, K. J. et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int. 70, 536-542 (2006).
22. Epstein, M. et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin. J. Am. Soc. Nephrol. 1, 940-951 (2006).
23. Morales, E. et al. Renoprotective effect of mineralocorticoid receptor blockers in patients with proteinuric kidney disease. Nephrol. Dial. Transplant. http://dx.doi.org/10.1093/ndt/gfs429.
24. Navaneethan, S. D., Nigwekar, S. U., Sehgal, A. R. & Strippoli, G. F. Aldosterone antagonists for preventing the progression of chronic kidney disease: A systematic review and meta-analysis. Clin. J. Am. Soc. Nephrol. 4, 542-551 (2009).
25. Nederlands Trial Register. trialregister.nl [online], http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=2133 (2012).
26. ONTARGET Investigators et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 358, 1547-1559 (2008).
27. Mann, J. F. et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 372, 547-553 (2008).
28. Ruggenenti, P. & Remuzzi, G. Proteinuria: Is the ONTARGET renal substudy actually off target? Nat. Rev. Nephrol. 5, 436-437 (2009).
29. Lambers-Heerspink, H. J. & de Zeeuw, D. Dual RAS therapy not on target, but fully alive. Nephron Clin. Pract. 116, c137-c142 (2010).
30. Tobe, S. W. et al. Cardiovascular and renal outcomes with telmisartan, ramipril or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies. Circulation 123, 1098-1107 (2011).
31. Parving, H. H. et al. Cardio-renal endpoints in a trial of aliskiren for type 2 diabetes. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1208799.
32. Parving, H. H. et al. Baseline characteristics in the aliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE). J. Renin Angiotensin Aldosterone Syst. 13, 387-393 (2012).
33. Fried, L. F. et al. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON D). Clin. J. Am. Soc. Nephrol. 4, 361-368 (2009).
34. Maione, A. et al. Protocol of the long-term impact of RAS inhibition on cardiorenal outcomes (LIRICO) randomized trial. J. Nephrol. 20, 646-655 (2007).
35. Chapman, A. B. et al. The HALT polycystic kidney disease trials: design and implementation. Clin. J. Am. Soc. Nephrol. 5, 102-109 (2010).
36. Gansevoort, R. T., de Zeeuw, D., Shahinfar, S., Redfield, A. & de Jong, P. E. Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease. J. Hypertens. Suppl. 12, S37-S42 (1994).
37. Miao, Y. et al. Increased serum potassium affects renal outcomes: A post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. Diabetologia 54, 44-50 (2011).
38. Slagman, M. C. et al. Erythropoietin is reduced by combination of diuretic therapy and RAAS blockade in proteinuric renal patients with preserved renal function. Nephrol. Dial. Transplant. 25, 3256-3260 (2010).
39. Mohanram, A., Zhang, Z., Shahinfar, S., Lyle, P. A. & Toto, R. D. The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes. Kidney Int. 73, 630-636 (2008).
40. Miao, Y. et al. Effect of a reduction in uric acid on renal outcomes during losartan treatment: A post hoc analysis of the reduction of endpoints in non insulin dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension 58, 2-7 (2011).
41. Smink, P. A. et al. An initial reduction in serum uric acid during angiotensin receptor blocker treatment is associated with cardiovascular protection: A post-hoc analysis of the RENAAL and IDNT trials. J. Hypertens. 30, 1022-1028 (2012).
42. Slagman, M. C. et al. Effects of antiproteinuric intervention on elevated connective tissue growth factor (CTGF/CCN 2) plasma and urine levels in nondiabetic nephropathy. Clin. J. Am. Soc. Nephrol. 6, 1845-1850 (2011).
43. Onuigbo, M. A. & Onuigbo, N. T. Late-onset renal failure from angiotensin blockade (LORFFAB) in 100 CKD patients. Int. Urol. Nephrol. 40, 233-239 (2008).
44. Onuigbo, M. A. & Onuigbo, N. T. Worsening renal failure in older chronic kidney disease patients with renal artery stenosis concurrently on renin angiotensin aldosterone system blockade: A prospective 50-month Mayo Health System clinic analysis. QJM 101, 519-527 (2008).
45. Onuigbo, M. A. Radiographic contrast-induced nephropathy and patient mortality. Mayo Clin. Proc. 83, 1412-1413 (2008).
46. Richer-Giudicelli, C. et al. Haemodynamic effects of dual blockade of the renin-angiotensin system in spontaneously hypertensive rats: Influence of salt. J. Hypertens. 22, 619-627 (2004).
47. Slagman, M. C. et al. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial. BMJ 343, d4366 (2011).
48. Nallamothu, B. K., Hayward, R. A. & Bates, E. R. Beyond the randomized clinical trial: The role of effectiveness studies in evaluating cardiovascular therapies. Circulation 118, 1294-1303 (2008).
49. Brenner, B. M. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861-869 (2001).
50. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349, 1857-1863 (1997).
51. Navis, G., de Jong, P., Donker, A. J., van der Hem G. K. & de Zeeuw, D. Diuretic effects of angiotensin-converting enzyme inhibition: Comparison of low and liberal sodium diet in hypertensive patients. J. Cardiovasc. Pharmacol. 9, 743-748 (1987).
52. Navis, G., de Jong, P. E., Donker, A. J., van der Hem, G. K. & de Zeeuw, D. Moderate sodium restriction in hypertensive subjects: renal effects of ACE-inhibition. Kidney Int. 31, 815-819 (1987).
53. MacGregor, G. A. et al. Moderate sodium restriction with angiotensin converting enzyme inhibitor in essential hypertension: A double blind study. Br. Med. J. (Clin. Res. Ed.) 294, 531-534 (1987).
54. Houlihan, C. A. et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care 25, 663-671 (2002).
55. Ekinci, E. I. et al. Effects of salt supplementation on the albuminuric response to telmisartan with or without hydrochlorothiazide therapy in hypertensive patients with type 2 diabetes are modulated by habitual dietary salt intake. Diabetes Care 32, 1398-1403 (2009).
56. Wapstra, F. H., Van Goor, H., Navis, G., de Jong, P. E. & de Zeeuw, D. Antiproteinuric effect predicts renal protection by angiotensin-converting enzyme inhibition in rats with established adriamycin nephrosis. Clin. Sci. (Lond.) 90, 393-401 (1996).
57. Vogt, L., Waanders, F., Boomsma, F., de Zeeuw, D. & Navis, G. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J. Am. Soc. Nephrol. 19, 999-1007 (2008).
58. Weir, M. R., Yadao, A. M., Purkayastha, D. & Charney, A. N. Effects of high- and low-sodium diets on ambulatory blood pressure in patients with hypertension receiving aliskiren. J. Cardiovasc. Pharmacol. Ther. 15, 356-363 (2010).
59. Buter, H., Hemmelder, M. H., Navis, G., de Jong, P. E. & de Zeeuw, D. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol. Dial. Transplant. 13, 1682-1685 (1998).
60. Ruggenenti, P. et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 354, 359-364 (1999).
61. Vegter, S. et al. Sodium intake, ACE inhibition, and progression to ESRD. J. Am. Soc. Nephrol. 23, 165-173 (2011).
62. Lambers-Heerspink, H. J. et al. Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. Kidney Int. 82, 330-337 (2012).
63. Vallon, V., Blantz, R. C. & Thomson, S. Glomerular hyperfiltration and the salt paradox in early [corrected] type 1 diabetes mellitus: A tubulo-centric view. J. Am. Soc. Nephrol. 14, 530-537 (2003).
64. Luik, P. T. et al. Short-term moderate sodium restriction induces relative hyperfiltration in normotensive normoalbuminuric type I diabetes mellitus. Diabetologia 45, 535-541 (2002).
65. Cook, N. R. et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: Observational follow-up of the trials of hypertension prevention (TOHP). BMJ 334, 885-888 (2007).
66. Taylor, R. S., Ashton, K. E., Moxham, T., Hooper, L. & Ebrahim, S. Reduced dietary salt for the prevention of cardiovascular disease. Cochrane Database of Systematic Reviews, Issue 7. Art. No.: CD009217. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009217/.
67. He, F. J. & MacGregor, G. A. Salt reduction lowers cardiovascular risk: meta-analysis of outcome trials. Lancet 378, 380-382 (2011).
68. Paterna, S., Gaspare, P., Fasullo, S., Sarullo, F. M. & di Pasquale, P. Normal-sodium diet compared with low-sodium diet in compensated congestive heart failure: Is sodium an old enemy or a new friend? Clin. Sci. (Lond.) 114, 221-230 (2008).
69. Kocks, M. J., Lely, A. T., Boomsma, F., de Jong, P. E. & Navis, G. Sodium status and angiotensin-converting enzyme inhibition: Effects on plasma angiotensin(1-7) in healthy man. J. Hypertens. 23, 597-602 (2005).
70. Kocks, M. J. et al. High dietary sodium blunts affects of angiotensin-converting enzyme inhibition on vascular angiotensin I to angiotensin II conversion in rats. J. Cardiovasc. Pharmacol. 42, 601-606 (2003).
71. Vogt, L., Kocks, M. J., Laverman, G. D. & Navis, G. Renoprotection by blockade of the reninYangiotensinYaldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance? Minerva Med. 95, 395-409 (2004).
72. Hamming, I., Navis, G., Kocks, M. J. & van Goor, H. ACE inhibition has adverse renal effects during dietary sodium restriction in proteinuric and healthy rats. J. Pathol. 209, 129-139 (2006).
73. Trongtorsak, P., Morgan, T. O. & Delbridge, L. M. Combined renin-angiotensin system blockade and dietary sodium restriction impairs cardiomyocyte contractility. J. Renin Angiotensin Aldosterone Syst. 4, 213-219 (2003).
74. Thomas, M. C. et al. The association between dietary sodium intake, ESRD, and all-cause mortality in patients with type 1 diabetes. Diabetes Care 34, 861-866 (2011).
75. O'Donnell, M. J. et al. Urinary sodium and potassium excretion and risk of cardiovascular events. JAMA 306, 2229-2238 (2011).
76. Ekinci, E. I. et al. Dietary salt intake and mortality in patients with type 2 diabetes. Diabetes Care 34, 703-709 (2011).
77. Visser, F. W., Krikken, J. A., Muntinga, J. H., Dierckx, R. A. & Navis, G. J. Rise in extracellular fluid volume during high sodium depends on BMI in healthy men. Obesity (Silver Spring) 17, 1684-1688 (2009).
78. Padmanabhan, S. et al. Genome-wide association study of blood pressure extremes identifies variant near UMOD associated with hypertension. PLoS Genet. 6, e1001177 (2010).
79. Slagman, M. C. et al. Elevated N terminal pro-brain natriuretic peptide levels predict an enhanced anti-hypertensive and anti-proteinuric benefit of dietary sodium restriction and diuretics, but not angiotensin receptor blockade, in proteinuric renal patients. Nephrol. Dial. Transplant. 27, 983-990 (2012).
80. van der Kleij, F. G. et al. Angiotensin converting enzyme insertion/deletion polymorphism and short-term renal response to ACE inhibition: role of sodium status. Kidney Int. Suppl. 63, S23-S26 (1997).
81. Lely, T. A. et al. Response to angiotensin-converting enzyme inhibition is selectively blunted by high sodium in angiotensin-converting enzyme DD genotype: Evidence for gene-environment interaction in healthy volunteers. J. Hypertens. 28, 2414-2421 (2010).
82. Krikken, J. A., Laverman, G. D. & Navis, G. Benefits of dietary sodium restriction in the management of chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 18, 531-538 (2009).
83. van den Berg, E. et al. Sodium intake and blood pressure in renal transplant recipients. Nephrol. Dial. Transplant. 27, 3352-3359 (2012).
84. de Zeeuw, D. et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): A randomised controlled trial. Lancet 376, 1543-1551 (2010).
85. Doorenbos, C. R., van den Born, J., Navis, G. & de Borst, M. H. Possible renoprotection by vitamin D in chronic renal disease: beyond mineral metabolism. Nat. Rev. Nephrol. 5, 691-700 (2009).
86. Nederlands Trial Register. trialregister.nl [online], http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=2898 (2012).